Osteoporosis Drugs Market Size was valued at USD 16.32 Billion in 2023. The Global Osteoporosis Drugs industry is projected to grow from USD 17.25 Billion in 2024 to USD 24.08 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.78% during the forecast period (2024 - 2032). Osteoporosis is a medical problem that causes low bone density. The low quality of bones and porous bones are common in this condition. In some cases, it can cause more pain and fractures in humans. The production of parathyroid hormones is high in osteoporosis patients. The health of the patients can gradually worsen without proper medication. The prevalence of osteoporosis is increasing the demand for the osteoporosis drugs market.
Bisphosphonates, parathyroid therapy, RANK and calcitonin are drugs available for osteoporosis. Oral administration and injections are available for the osteoporosis condition. The therapeutic benefits of osteoporosis drugs are plenty. It can help the patient to control the condition. Also, it can improve the bone condition. Positive results of the osteoporosis drugs create an exceptional demand for the osteoporosis drugs market. The osteoporosis drug market is expected to witness tremendous developments in the forecast period. Faster adoption of the osteoporosis drug is leading to more growth opportunities for the market. The rise in the osteoporosis condition will improve the market operations and production.
Covid analysis
Covid 19 is creating damaging effects on many global industries. In the medical sector, only essential treatments have high demand. The pandemic is reducing the demand for the osteoporosis drugs market. The osteoporosis’s patients are delaying their treatment due to covid 19. Due to lockdowns and restrictions, the number of patients visiting hospitals for other treatment is declining. The supply chain of osteoporosis drugs disrupted during this period.
The cases of osteoporosis in hospitals have considerably decreased in hospitals. These factors decline the overall demand of the osteoporosis drugs market. However, the market is under extensive research. There is expected to be more drug developments post covid 19. Innovation, the launch of new products and effective drugs is possible in this market. The market is expected to surge once the lockdowns and restrictions in hospitals reduce. The regions such as North America are allocating massive investments for the osteoporosis drugs market in this period. These investments will enhance the medical and drugs standards of the osteoporosis drugs market. Also, the revenue rate is expected to rise significantly in the upcoming years.
The F.D.A. approved Wyost/Jubbonti, the first biosimilar to reference Xgeva/Prolia (denosumab) in the U.S., in March 2024.1 The two drugs may be used to cure or prevent osteoporosis and hypercalcemia as well as avoid skeletal-related events triggered by bone metastases from solid tumors. In February 2023, Sandoz filed a biologics license application for Wyost/Jubbonti with the F.D.A. Moreover, denosumab biosimilars have not yet been approved for use in European Union countries. This happened immediately after Canada authorized these same products last month.
Teriparatide Injection by Apotex Corp is now available in the United States as a single-patient-use pre-filled pen for osteoporosis treatment. It is called Teriparatide Injection and has a concentration of 250 mcg/mL, which means each pen provides twenty-eight 20 mcg doses per day to one patient only. The global operation of this company is led by Apotex Corp., whose headquarters are also located in Weston, Florida. In terms of generic pharmaceuticals and biosimilars, they stand among the world’s best with their affordable, highly effective drugs in all major therapeutic areas.
Fujitsu Limited and iSurgery Co., Ltd have announced their field-trial plan called “bone health promotion project” from October 2023 to March 2025 together with Jikei University School of Medicine Department of Orthopedic Surgery to find out if chest x-rays can be used for bone assessment purposefully and whether Fujitsu staff will then change their attitude to health or their physical exercise.“Bone assessments conducted via chest radiographs” marks the first time Japanese companies started focusing on improvement of their workers’ health in this regard during their check-ups.
Teva Pharmaceuticals Inc., an affiliate company based in the U.S. under Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that it received approval for a generic version of Forteo®1 for use in America. Therefore, it should be on sale in the U.S.A. within several weeks’ time. However, only F.D.A. has cleared off a few out of approximately five hundred generics, including Forteo®1 generics. They have over one hundred first-to-file applications lodged with them in the U.S.A., making them outperform other multinational pharmaceutical companies in terms of number one ranking. Among all low-cost generic prescriptions written within the U.S., every twelfth prescription was filled with a product from the Teva generics.
The growth potential for osteoporosis drugs is higher in emerging markets. The developing economies do not have standard treatment or drugs for a specific illness. There is variation in drugs available for a condition. More penetration of osteoporosis drugs in developing economies will lead to a higher rate of adoption. Emerging markets will lead osteoporosis drugs market growth opportunities. The awareness about osteoporosis is high among the developed markets. However, in many regions, the awareness about this condition is less.
With increased awareness, the demand for drugs will increase immensely. In the forecast period, market expansion strategies are crucial for the key players. Promising growth opportunities are waiting in the emerging market. The growth of the osteoporosis drugs market in such regions will lead to plenty of developments. The entry of new key players will lead to innovation and product variation. Also, these factors will attract new end users to the market.
Side effects of osteoporosis drugs are a major market restraint. Like any other drug, osteoporosis will lead to common side effects. It is the primary concern and limitation of the drug market. In some cases, the stomach may not respond properly to the osteoporosis drugs. Stomach burn and heartburn are some of the side effects that hamper osteoporosis drugs market growth.
With proper tips from clinicians and diet, these effects are manageable. There are types of osteoporosis drugs on the market. More than the risks the benefits of the medication are more. Choosing the right drugs can lead to fewer side effects. However, these side effects create hesitation among patients. As per osteoporosis drugs market report, this can affect the demand trend of the market.
Most of the clinical drugs have delayed approval from the health sector and government. The stringent regulatory norms and compliance standards to get drugs approval is a significant challenge. These challenges delay the supply process and slow down the production of the osteoporosis drugs market. The osteoporosis drugs research is expensive.
After new drug development, the late approval affects the demand and exposure of the new product. Also, the poor efficacy of the drug is another challenge of the market. The osteoporosis drugs may not immediately cure the bone problem. It acts gradually by strengthening the weak bone of the patient. Due to this, osteoporosis drugs are considered less efficient. These market challenges can hinder the overall growth rate of the osteoporosis drugs market.
The growth trend of the osteoporosis treatment market remains stable in the forecast period. The rise in the geriatric population propels the overall demand for the osteoporosis drugs market. Also, the low one density issues in the female population in yet another crucial driver. The application segments of the osteoporosis drugs market lead to more profitability.
The wide range of applications attracts plenty of end-users. The growth possibilities for osteoporosis drugs are high in emerging economies. The expansion of the market in this region will create plenty of growth opportunities. Side effects of the drug and poor efficacy are considered a major challenge. Overall the growth analysis of the market shows a positive outcome.
North America is accountable for major osteoporosis drugs market shareholdings. This positive growth trend in the market will continue in the forecast period. Access to osteoporosis drugs is high in this region.
The prevalence of bone problems is high in this region. A sedimentary lifestyle of individuals is leading to more osteoporosis cases. Due to this, the growth rate is immense in the forecast period. The presence of top market players will result in plenty of market improvements. New drug launches and innovations will create more growth possibilities.
Competitive landscape
The global osteoporosis drugs market is immensely competitive. The key players are taking plenty of steps to maximize their shares. The product launch, collaboration, partnership and acquisition are key strategies of the competitive landscape. Innovative drugs developments are happening in the competitive landscape. Also, the market expansion is going to be tremendous during the forecast period.
Regional analysis
The osteoporosis drugs market is fragmented into Asia Pacific, Europe, and North America. North America will dominate the market with the highest demand rate. The prevalence of osteoporosis contributes to the high market growth. The Asia Pacific is the next largest market with the highest growth rate.
The pharmaceutical industry in this region is gaining more traction in the forecast period. Evolving industry such as Malaysia, China and India are growing at an exponential rate. Europe has moderate demand with a high expansion rate. The penetration of osteoporosis drugs is massive in Europe. Further, the expansion of osteoporosis will increase in Latin America and other regions.
The key players of the osteoporosis drugs market
Recent developments
Report overview
| Report Attribute/Metric | Details |
| Â Â Market Size | Â Â USD 24.08 Billion |
| Â Â CAGR | Â Â 2024-2032: 3.78% |
| Â Â Base Year | Â Â 2023 |
| Â Â Forecast Period | Â Â 2032 |
| Â Â Historical Data | Â Â 2018 |
| Â Â Forecast Units | Â Â Value (USD Billion) |
| Â Â Report Coverage | Â Â Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Â Â Segments Covered | Â Â Drug Class, Route of Administration, Gender |
| Â Â Geographies Covered | Â Â North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Â Â Key Vendors | Â Â Eli Lilly and Company, Merck & Co., Novartis International AG, Amgen Inc., F. Hoffmann La Roche Ltd., Pfizer Inc., Novo Nordisk, Teva Pharmaceutical Industries Ltd |
| Â Â Key Market Opportunities | Â Â Research and developments |
|   Key Market Drivers | · Rise in the geriatric population· Increased screening· Drug induced osteoporosis· Increased awareness and focus towards female health· Rising prevalence of diseases |
Osteoporosis Drugs Market Highlights:
Frequently Asked Questions (FAQ) :
The global osteoporosis drugs market is expected to thrive at a CAGR of 3.78% from 2024 to 2032.
The global osteoporosis drugs market size can inflate to USD 24.08 Billion by 2032.
The global osteoporosis drugs market stood at USD 24.08 Billion in 2032.
Drug induced osteoporosis, rise in the numbers of the geriatric populace, and focus towards female health are major drivers of the global osteoporosis drugs market.
Patent expiry of blockbuster drugs, large penetration of generics, and side-effects of current treatments are major challenges of the global osteoporosis drugs market.
The Americas can dominate the global osteoporosis drugs market due to large prevalence of osteoporosis among the elderly.
Pfizer Inc., Merck & Co., Amgen Inc., Novo Nordisk, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Eli Lilly and Company, and Novartis International AG are the major players of the global osteoporosis drugs market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
